# Pharmaceuticals Research Performance Dashboard

## Executive Summary
**Report Period:** Q3 2025 (2025-07-01 to 2025-09-30)
**Last Updated:** 2025-10-01

## Key Performance Indicators

### Financial Metrics
- **R&D Investment**: $125M (Current Quarter)
  - YoY Growth: +8.7%
  - QoQ Growth: +4.2%
  - Historical: Q1: $115M, Q2: $120M, Q3: $125M, Q4: $130M (projected)
- **R&D Costs**: $118M
  - YoY Change: +7.3%
  - Cost per project: $4.2M
  - Historical trend: Q1: $108M, Q2: $112M, Q3: $118M
- **R&D Efficiency**: 85.2%
  - Target: 80.0%
  - Historical: 82.1% (2024) → 84.5% (2025)

### Operational Metrics
- **Active Projects**: 28 research programs
  - Monthly average: 9.3 programs
  - Peak month: 11 programs (August)
  - Trend: July: 8, August: 11, September: 9
- **Drug Candidates**: 12 in pipeline
  - Target: 15 by year-end
  - Phase distribution: Discovery: 8, Preclinical: 3, Clinical: 1
- **Patent Filings**: 7 (Quarter)
  - Target: 8 per quarter
  - Monthly performance: July: 2, August: 3, September: 2

### Time-Based Metrics
- **Time to IND**: 18.5 months (average)
  - Fastest: 14.2 months
  - Slowest: 24.1 months
  - Trend: Q1: 19.2 months, Q2: 18.8 months, Q3: 18.5 months
- **Screening Throughput**: 50,000 compounds/day
  - Target: 45,000
  - Monthly performance: July: 48K, August: 52K, September: 50K

## Trend Analysis

### Year-over-Year Comparison
| Metric | 2024 | 2025 (YTD) | Change |
|--------|------|------------|--------|
| R&D Spend | $450M | $360M | -20.0% |
| Active Projects | 32 | 28 | -12.5% |
| Drug Candidates | 14 | 12 | -14.3% |
| Patent Filings | 28 | 21 | -25.0% |

### Monthly Trend Data (Last 12 Months)
| Month | R&D Spend ($M) | Active Projects | Candidates | Patents |
|-------|----------------|----------------|------------|----------|
| Oct 2024 | 35.2 | 30 | 13 | 3 |
| Nov 2024 | 36.1 | 31 | 13 | 2 |
| Dec 2024 | 37.5 | 32 | 14 | 4 |
| Jan 2025 | 32.1 | 28 | 12 | 2 |
| Feb 2025 | 33.2 | 28 | 12 | 1 |
| Mar 2025 | 34.5 | 29 | 12 | 3 |
| Apr 2025 | 35.8 | 29 | 12 | 2 |
| May 2025 | 36.2 | 29 | 12 | 2 |
| Jun 2025 | 36.8 | 29 | 12 | 3 |
| Jul 2025 | 37.1 | 28 | 12 | 2 |
| Aug 2025 | 38.2 | 28 | 12 | 3 |
| Sep 2025 | 37.5 | 28 | 12 | 2 |

## Forecasting
- **Q4 Projection**: $130M R&D spend (±8% confidence)
- **Annual Target**: $500M (96% to goal)
- **Risk Factors**: Clinical trial delays, regulatory changes

## Benchmarking
- **Industry Average**: 15-20 drug candidates in pipeline
- **Top Quartile**: 25+ candidates, 40+ patent filings annually
- **Competitive Position**: Mid-tier pharma with solid pipeline progression
